OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Transplant donation without discrimination	256
How do we prevent anal cancer in people living with HIV?	142
Argentina updates HIV laws	139
Evidence supports use of on-demand PrEP for HIV prevention	138
How much could long-acting PrEP cost in South Africa?	135
The Australian AIDS crisis through the eyes of volunteers	134
Correction to Lancet HIV 2022; 9: e791–800	133
HIV and COVID-19: juxtaposition of two pandemics	108
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	105
Optimising anal cancer screening through risk stratification	101
Controversial chronicler of LGBTQ rights	97
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	95
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	86
Risk estimation in HIV reveals our usual blind spots	82
Steps toward quick and equitable roll-out of lenacapavir	82
Are we ready for long-acting HIV treatment for adolescents?	79
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	76
Lenacapavir: an attractive option, but proceed with caution	72
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	72
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	71
Lung cancer in people living with HIV	64
A moment of reckoning	63
Redefining care: injectable HIV treatment for adolescents	59
All roads lead to Westminster: the infected blood scandal	57
Unheard testimony	53

Fate of people with HIV in jeopardy in Ukraine	52
Gains and gaps: addressing HIV in diverse sex worker groups	52
Stigma reduction is key to improving the HIV care continuum	50
Game-changing study of second-line HIV treatment	49
Reducing HIV transmission in British Columbia, Canada	47
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	46
Recent gay Black history in the UK	46
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	45
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	44
Suicide prevention research is crucial to achieving health equity for people with HIV	44
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	43
Equitable access to long-acting PrEP on the way?	42
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	42
Sex as a biological variable in HIV-1 and schistosome co-infection	42
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	42
A public health approach to drug use crucial to ending AIDS	40